Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Axsome Therapeutics, Inc. (AXSM)

71.96   1.23 (1.74%) 09-26 15:33
Open: 70.73 Pre. Close: 70.73
High: 73.165 Low: 70.585
Volume: 306,494 Market Cap: 3,528(M)

Technical analysis

as of: 2023-09-26 3:17:37 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 91.59     One year: 97.29
Support: Support1: 70.52    Support2: 58.68
Resistance: Resistance1: 78.42    Resistance2: 83.3
Pivot: 76.49
Moving Average: MA(5): 73.01     MA(20): 77.34
MA(100): 75.76     MA(250): 68.16
MACD: MACD(12,26): -1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 9.3     %D(3): 12.5
RSI: RSI(14): 41.8
52-week: High: 91.29  Low: 38.86
Average Vol(K): 3-Month: 742 (K)  10-Days: 736 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AXSM ] has closed above bottom band by 22.3%. Bollinger Bands are 10% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 73.57 - 74.07 74.07 - 74.48
Low: 69.6 - 70.07 70.07 - 70.46
Close: 70.04 - 70.8 70.8 - 71.44

Company Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Headline News

Tue, 26 Sep 2023
Mizuho Reiterates Axsome Therapeutics (AXSM) Buy ... - Nasdaq

Tue, 26 Sep 2023
Axsome Therapeutics Inc (AXSM) is lower by -1.27% in a Week, Should You Hold? - InvestorsObserver

Mon, 25 Sep 2023
Analyst Ratings for Axsome Therapeutics - Axsome Therapeutics ... - Benzinga

Mon, 25 Sep 2023
Optimistic Outlook for Axsome Therapeutics Analysts Predict ... - Best Stocks

Fri, 22 Sep 2023
Axsome Therapeutics Joins the Global Narcolepsy Community in ... - BioSpace

Thu, 14 Sep 2023
Is Axsome Therapeutics Inc (AXSM) a Winner in the Biotechnology Industry? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 47 (M)
Shares Float 35 (M)
% Held by Insiders 17.1 (%)
% Held by Institutions 70.6 (%)
Shares Short 8,240 (K)
Shares Short P.Month 9,060 (K)

Stock Financials

EPS -4.41
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.96
Profit Margin (%) -101.1
Operating Margin (%) -88.9
Return on Assets (ttm) -25.6
Return on Equity (ttm) -125.5
Qtrly Rev. Growth 429.5
Gross Profit (p.s.) 0.97
Sales Per Share 3.86
EBITDA (p.s.) -3.39
Qtrly Earnings Growth 0
Operating Cash Flow -111 (M)
Levered Free Cash Flow -27 (M)

Stock Valuations

PE Ratio -16.43
PEG Ratio -0.2
Price to Book value 12.13
Price to Sales 18.72
Price to Cash Flow -30.66

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.